NMPA Approves Toripalimab in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma after Failure of at Least Two Lines of Prior Systemic Therapy

— 1st approval of any checkpoint inhibitor in nasopharyngeal carcinoma in the world

— 2nd indication approved for Toripalimab in China

SHANGHAI, China, Feb. 22, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and
commercialization of novel therapies, announced today that